Previous 10 | Next 10 |
Gainers: Itamar Medical ITMR +45%, aTyr Pharma LIFE +35%, iRhythm Technologies (NASDAQ:IRTC) +33%, REGENXBIO RGNX +20%, Leap Therapeutics LPTX +15%. Losers: MiMedx MDXG -61%, Silverback Therapeutics (NASDAQ:SBTX) -24%, Dynavax T...
CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, t...
The following slide deck was published by Checkmate Pharmaceuticals, Inc. in conjunction with this event. For further details see: Checkmate Pharmaceuticals (CMPI) Investor Presentation - Slideshow
Clinical trial programs for vidutolimod (CMP-001) in melanoma and head and neck cancer indications ongoing Trial start-up activities to support non-melanoma skin cancer indications underway Multiple clinical data readouts anticipated in 2022 CAMBRIDGE, Mass., A...
Checkmate Pharmaceuticals Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that Barry Labinger, CEO, will present a...
CAMBRIDGE, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, toda...
Checkmate Pharmaceuticals (CMPI): Q1 GAAP EPS of -$0.65 beats by $0.02.Cash, cash equivalents and available-for-sale investments of $111.5M.Press Release For further details see: Checkmate Pharmaceuticals EPS beats by $0.02
CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today an...
Checkmate Pharmaceuticals (CMPI) announces the development program expansion of vidutolimod (CMP-001) into non-melanoma skin cancers in combination with Libtayo (cemiplimab) under a clinical supply agreement with Regeneron Pharmaceuticals (REGN). Checkmate and Regeneron will collaborate on a ...
CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today an...
News, Short Squeeze, Breakout and More Instantly...
Checkmate Pharmaceuticals Inc. Company Name:
CMPI Stock Symbol:
NASDAQ Market:
Checkmate Pharmaceuticals Inc. Website:
Ad-hoc announcement pursuant to Article 53 of the SIX listing rules • $2.5 million of milestone to be paid to XOMA Corporation under royalty agreement SCHLIEREN (ZURICH), Switzerland, June 02, 2022 (GLOBE NEWSWIRE) -- Kuros Biosciences AG (“Kuros” ...
CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat c...
CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (Nasdaq: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today an...